A Clinician´s Guide to Biosimilars in Oncology: Understanding the Science of Extrapolation and Interchangeability Elena Wolff-Holz, MD Paul-Ehrlich Institute, Germany Chair of the European Medicines Agency’s Biosimilar Medicinal Products Working Party (BMWP) Member of the Oncology Working Party (OWP) Alternate member of the Scientific Advice Working Party (SAWP)
Biosimilars: what oncologists need to know Fernando de Mora Perez, PhD, MBA, from the Autonomous University of Barcelona, Barcelona, Spain, tells us why oncologists need further education on biosimilars. He discusses the reasons why they should be confident that these medicines will be just as safe and effective as the originator brands. This video was recorded at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain.
In the context of the ESMO 2017 industry satellite symposium: Biosimilars for Oncologists: what you need to know, Fernando de Mora, Professor of Pharmacology – Autonomous University of Barcelona, is interviewed by Suzette Kox, Senior Director International – Biosimilar Medicines Group